Trinity Biotech

Trinity Biotech EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Trinity Biotech (TRIB) as of Nov 9, 2026 is 3.36. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 1.79 — a change of 88.21% (higher).

EV/Revenue

3.36

YoY

88.21%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Trinity Biotech is 2025 3.36 . EV/Revenue (Enterprise Value to Revenue) of Trinity Biotech was 2024 1.79 . It decreases by 88.21% higher compared to the previous year.

The Trinity Biotech EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2018
0.68 USD
Jan 1, 2019
1.11 USD
Jan 1, 2020
0.90 USD
Jan 1, 2021
1.08 USD
Jan 1, 2022
1.28 USD
Jan 1, 2023
1.37 USD
Jan 1, 2024
1.79 USD
Jan 1, 2025
3.36 USD
The Trinity Biotech EV/Revenue history
YEAREV/RevenueYoY
3.36+88.21%
1.79+30.00%
1.37+7.42%
1.28+18.50%
1.08+20.49%
0.90-19.08%
1.11+62.45%
0.68+30.13%
0.52+53.42%
0.34+227.68%
0.10-43.52%
0.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

EV/Revenue (Enterprise Value to Revenue) of Trinity Biotech is 3.36 in 2025.

EV/Revenue (Enterprise Value to Revenue) of Trinity Biotech changed from 1.79 to 3.36, representing a 88.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Trinity Biotech

All Key Metrics — Trinity Biotech